证券代码：002900 证券简称：哈三联 公告编号：2023-060 哈尔滨三联药业股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下简称"公司"）第四届监事会第七次 会议于 2023 年 8 月 11 日以书面及电子邮件形式向全体监事发出通知。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、监事会会议审议情况 1、审议通过《关于 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审议公司 2023 年半年度报告的程序符合 法律、行政法规和中国证监会的相关规定，报告内容真实、准确、完整地反映了 上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决情况：同意 3 票；反对 0 票；弃权 0 票 表决结果：通过。 2、本次会议于 2023 年 8 月 23 日在公司会议室以现场表决方式召开。 3、本次会议应到监事 3 ...

第四届董事会第十次会议决议公告 证券代码：002900 证券简称：哈三联 公告编号：2023-059 哈尔滨三联药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届董事会第十 次会议于 2023 年 8 月 11 日以书面及电子邮件形式向全体董事发出通知。 2、本次会议于 2023 年 8 月 23 日以现场结合通讯表决的方式召开。 3、本次会议应到董事 9 名，实际出席并表决的董事 9 名。 4、公司董事长秦剑飞先生主持了会议，公司监事及总裁列席。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、董事会会议审议情况 会议审议并通过以下议案： 1、审议通过《关于 2023 年半年度报告全文及摘要的议案》 表决情况：同意 9 票，反对 0 票，弃权 0 票。 表决结果：通过。 《2023 年半年度报告全文》请详见同日刊登在公司指定信息披露网站巨潮 资讯网（http ...

法律意见书 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席本 次股东大会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》、 《股东大会规则》等法律、法规、规范性文件及《公司章程》的规定发表意见， 北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于哈尔滨三联药业股份有限公司 2023 年第三次临时股东大会的 法律意见书 致：哈尔滨三联药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为哈尔滨三联药业股份有限 公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2023 年第三次临时股东大会（以下简称"本次股东大会"）。本所律师根据《中华人 民 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002900 证券简称：哈三联 公告编号：2023-058 哈尔滨三联药业股份有限公司 2023 年第三次临时股东大会决议公告 1、本次股东大会无否决议案或修改议案的情况；本次股东大会上无新提议 案提交表决； 2、本次股东大会不涉及变更前次股东大会决议的情况； 3、本次股东大会因涉及审议影响中小投资者利益的重大事项，公司将对中小 投资者表决情况进行单独计票。中小投资者是指以下股东以外的其他股东： （1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东。 一、会议召开情况 1、会议召开时间： （1）现场会议召开时间：2023 年 8 月 21 日（周一）15:30； （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2023 年 8 月 21 日 9:15-9:25，9:30-11:30，13:00-15:00； 二、会议出席情况 1、出席的总体情况 参加本次股东大会现场会议和网络投票的股东（代理人）共计 6 名，代表股 份数为 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司收到控股子公司黑龙江哈三联生物技术创新 中心有限公司的通知，其对法定代表人进行了变更，并已完成工商变更登记手续， 取得了哈尔滨新区管理委员会行政审批局换发的《营业执照》。具体变更情况如 下： 变更前： 证券代码：002900 证券简称：哈三联 公告编号：2023-057 哈尔滨三联药业股份有限公司 关于控股子公司变更法定代表人并完成工商变更登记的公告 法定代表人：张道旭 备查资料 1、黑龙江哈三联生物技术创新中心有限公司营业执照。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2023 年 8 月 17 日 变更后： 法定代表人：李宏伟 除法定代表人变更外，黑龙江哈三联生物技术创新中心有限公司《营业执照》 的其他登记事项均保持不变。 ...

证券代码：002900 证券简称：哈三联 公告编号：2023-033 哈尔滨三联药业股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者网上集体接待日活 动暨业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2023 年 5 月 15 日（周一）14:00-16:30。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前 ...

（问题征集专题页面二维码） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2023 年 5 月 15 日（周一）14:00-16:30。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 12 日（周五）12:00 前访问 https://ir.p5w.ne ...

Financial Performance - The company's revenue for Q1 2023 was CNY 342,147,502.19, representing a 33.29% increase compared to CNY 256,694,410.27 in the same period last year[5] - Net profit attributable to shareholders reached CNY 39,163,800.70, a significant increase of 3,445.73% from a loss of CNY 1,170,560.94 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 20,511,251.64, up 422.73% from CNY 3,923,905.57 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.13, compared to a loss of CNY 0.02 per share in the same quarter last year, reflecting a 750.00% increase[5] - Total operating revenue for Q1 2023 reached CNY 342,147,502.19, a 33.33% increase from CNY 256,694,410.27 in Q1 2022[21] - Net profit for Q1 2023 was CNY 38,293,510.10, compared to a net loss of CNY 1,819,460.26 in the same period last year[22] - Operating profit for Q1 2023 was CNY 43,300,037.81, a significant recovery from a loss of CNY 2,724,332.84 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was CNY 26,205,083.12, a turnaround from a negative CNY 7,765,583.82, marking a 437.45% improvement[5] - Cash flow from operating activities was CNY 312,367,935.53, compared to CNY 254,545,834.16 in Q1 2022, indicating improved cash generation[24] - Total cash inflow from operating activities reached ¥336,143,482.69, up from ¥260,304,215.74 in the same period last year, indicating a growth of approximately 29.1%[25] - Cash outflow from operating activities was ¥309,938,399.57, compared to ¥268,069,799.56 in Q1 2022, reflecting an increase of about 15.7%[25] - The net cash flow from investing activities was -¥43,328,299.74, a decline from a positive cash flow of ¥447,183,988.76 in Q1 2022[25] - The net cash flow from financing activities was ¥46,866,238.08, an increase from ¥26,603,539.27 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,386,123,646.22, a 3.34% increase from CNY 3,276,788,333.47 at the end of the previous year[5] - Total liabilities increased to CNY 1,295,843,183.87 from CNY 1,224,801,381.22 year-over-year[19] - The company's equity attributable to shareholders was CNY 2,079,834,612.44, up 1.92% from CNY 2,040,670,811.74 at the end of the last year[5] - Long-term investments increased to CNY 655,019,843.89, up from CNY 646,866,264.65, indicating a stable investment strategy[19] Research and Development - The company increased its investment in research and development, with development expenditures rising by 50.43% to CNY 15,898,085.31 from CNY 10,568,155.52[9] - Research and development expenses increased to CNY 20,228,682.35, up from CNY 15,964,277.61 in the previous year, reflecting a focus on innovation[21] Other Income and Expenses - The company reported a significant increase in other income, which reached CNY 11,375,287.99, a 730.23% rise from CNY 1,370,131.73 in the previous year[11] - The fair value change income was CNY 7,145,181.77, a 175.90% increase compared to a loss of CNY 9,413,631.01 in the same period last year[11] - The company paid ¥32,750,632.17 in various taxes, which is a 33.78% increase compared to the same period last year, attributed to higher revenue[12] Shareholder Information - The top shareholder, Qin Jianfei, holds 39.07% of the shares, with a total of 123,705,000 shares, indicating strong insider ownership[14]

Financial Performance - The company's operating revenue for 2022 was ¥1,028,413,617.71, an increase of 8.73% compared to ¥945,799,422.97 in 2021 [20]. - The net profit attributable to shareholders for 2022 was ¥30,210,042.44, a decrease of 91.39% from ¥350,951,064.21 in 2021 [20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,860,891.68, a significant increase of 107.31% compared to -¥148,479,133.39 in 2021 [20]. - The net cash flow from operating activities reached ¥144,641,853.00, a remarkable increase of 1,254.01% from -¥12,533,851.80 in 2021 [20]. - The total assets at the end of 2022 were ¥3,276,788,333.47, reflecting a growth of 6.89% from ¥3,065,517,046.80 at the end of 2021 [20]. - The net assets attributable to shareholders decreased by 2.89% to ¥2,040,670,811.74 at the end of 2022 from ¥2,101,449,040.99 at the end of 2021 [20]. - The basic earnings per share for 2022 was ¥0.10, down 91.15% from ¥1.13 in 2021 [20]. - The weighted average return on equity for 2022 was 1.46%, a decrease of 16.65% from 18.11% in 2021 [20]. - The company reported a total of ¥19,349,150.76 in non-recurring gains for 2022, compared to ¥499,430,197.60 in 2021 [25]. - The company reported a cash dividend of 1.00 yuan per 10 shares, amounting to a total cash dividend of 31,656,005 yuan, which represents 100% of the total profit distribution [150]. Risk Management - The company faces various risks including industry policy risks, drug research and development risks, and fluctuations in raw material prices [4]. - The company has a comprehensive risk management strategy to address potential investment risks and ensure shareholder value [4]. Business Operations - The company has not reported any changes in its main business since its listing, indicating stability in operations [19]. - The company has maintained its full ownership of several subsidiaries, indicating a strong control over its business operations [14]. - The company has a dedicated investor relations team to facilitate communication with shareholders and stakeholders [17]. - The company has established a competitive salary policy that includes fixed and performance-based components to incentivize employee performance [146]. Product Development - The company has a total of 153 drug varieties and 254 production licenses, with 149 varieties included in the national medical insurance directory and 48 in the national essential drug list [30]. - The company has obtained drug registration certificates for six products during the reporting period, including Edaravone Injection and Olanzapine Oral Disintegrating Tablets, enhancing its product portfolio [33]. - The company has launched three oral health products in the health sector, focusing on cardiovascular health, beauty, and sleep improvement, utilizing beneficial ingredients like GABA and DHA [36]. - The company is focusing on the development of new health products, which are expected to drive revenue growth in the coming years [66]. - The company is enhancing its injection product quality through consistency evaluations for products like 克林霉素磷酸酯注射液 and 甲硝唑氯化钠注射液, which will strengthen its competitive position [64]. Market Trends - The pharmaceutical industry in China is expected to continue growing due to increasing healthcare demands driven by an aging population and improved living standards [28]. - The Chinese pharmaceutical industry is undergoing a transformation driven by the "14th Five-Year Plan," emphasizing innovation and quality compliance as key themes for high-quality development [29]. - The ongoing national drug procurement reform has expanded to include biological products and traditional Chinese medicine, which will accelerate the elimination of weaker pharmaceutical companies [29]. - The pharmaceutical industry is expected to see intensified competition focused on cost control and quality improvement in the future [29]. Corporate Governance - The company emphasizes the importance of accurate financial reporting and has confirmed the integrity of its annual report by its board of directors [4]. - The company maintains a complete and independent business system, ensuring no asset or financial encroachment by controlling shareholders [118]. - The company has established independent financial departments and accounting systems, ensuring no interference from controlling shareholders in financial decisions [119]. - The company has a clear governance structure with defined roles and responsibilities across its departments [119]. Environmental Responsibility - The company has implemented measures to ensure compliance with environmental protection laws and standards, including the discharge of pollutants [162]. - The company invested over 1 million yuan in environmental protection since its establishment, with more than 500,000 yuan spent in 2022 on pollution detection and waste disposal [176]. - The company has established a waste storage facility for hazardous waste, complying with national standards, and has a contract for safe disposal with a local environmental company [168]. Employee Engagement - A total of 677,000 restricted shares were granted to 175 core talents as part of the equity incentive program, enhancing employee engagement [47]. - The company has a structured training program aimed at enhancing employee skills and management capabilities, with a focus on continuous development [147]. - The total number of employees at the end of the reporting period was 1,721, with 1,293 in the parent company and 428 in major subsidiaries [144]. Future Outlook - The company plans to enhance cost control and resource allocation to ensure the achievement of annual operational targets [105]. - The management has indicated a positive outlook for future growth, with expectations of increased revenue and market share in the coming years [125]. - The company is exploring potential acquisitions to further strengthen its product portfolio and market presence [131].

索 引 号 bm56000001/2017-00005754 分 类 预先披露;预先披露 哈尔滨三联药业股份有限公司首次公开发行股票并上市招股说明书 （申报稿 2017年4月17日报送） 根据《证券法》第二十一条和《首次公开发行股票并上市管理办法》第五十八条、《首次公开发行股票并在创业 板上市管理办法》第四十条的规定，申请文件受理后、发行审核委员会审核前，发行人应当将招股说明书（申报稿） 在中国证监会网站预先披露。 发布机构 证监会 发文日期 【打印】 【关闭窗口】 名 称 哈尔滨三联药业股份有限公司首次公开发行股票并上市招股说明书（申报稿 2017年4月17日 报送） 文 号 主 题 词 ...